medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2015, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2015; 60 (2)

Group A streptococcus toxic shock syndrome

Torres AO, Olvera GC, Terrés TF, Aguirre SJ, Franco GJ

Language: Spanish
References: 31
Page: 118-124
PDF size: 187.98 Kb.


ABSTRACT

Toxic shock syndrome is a critical condition that develops from an immunological response from the host, targeted to a limited group of microbiological agents. The pathogenesis of the disease is complex, and involves antigenic factors from the pathogen that react with a series of inflammatory molecules released by the host. The management and treatment of toxic shock syndrome must be based on strong clinical evidence, it may represent a true challenge, and requires an early diagnosis. We present the case of a patient admitted to de Intensive Care Unit, who develops toxic shock syndrome from a soft tissue infection localized in the perineal region. The treatment involved measures to control a case of multiple organic failure in a setting of septic shock. Ultimately, the patient presented loss of distal-limb-structures besides an intense and adequate treatment, which was essential to stop progression to a fatal state. The objective of this review is to emphasize the importance of early diagnosis and treatment as there is not a frequent disease in our medium.


REFERENCES

  1. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet. 1978; 2 (8100): 1116-1118.

  2. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980; 303 (25): 1436-1442.

  3. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980; 303 (25): 1429-1435.

  4. Massell BF, Chute CG, Walker AM, Kurland GS. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med. 1988; 318 (5): 280-286.

  5. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis. 1989; 11 (6): 928-953.

  6. Wolf JE, Rabinowitz LG. Streptococcal toxic shock-like syndrome. Arch Dermatol. 1995; 131 (1): 73-77.

  7. Margolis DJ, Horlick SE. Group A streptococcus-induced bullous toxic shock-like syndrome. J Am Acad Dermatol. 1991; 24 (5 Pt 1): 786-787.

  8. Kellum JA. KDIGO clinical practice guideline for acute kidney injury. Kidney International [consulta 29/06/15]. Available in: http://kdigo.org/home/guidelines/acute-kidney-injury/

  9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41 (2): 580-637.

  10. Low DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit Care Clin. 2013; 29 (3): 651-675.

  11. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis. 1998; 27 (6): 1428-1436.

  12. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992; 14 (1): 2-11.

  13. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321 (1): 1-7.

  14. Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schalén C et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007; 45 (4): 450-458.

  15. Lepoutre A, Doloy A, Bidet P, Leblond A, Perrocheau A, Bingen E et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol. 2011; 49 (12): 4094-4100.

  16. O’Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007; 45 (7): 853-862.

  17. Ekelund K, Skinhřj P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol. 2005; 43 (4): 1789-1796.

  18. O’Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis. 2002; 35 (3): 268-276.

  19. Haywood CT, McGeer A, Low DE. Clinical experience with 20 cases of group A streptococcus necrotizing fascitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg. 1999; 103 (6): 1567-1573.

  20. Johansson L, Thulin P, Low DE, Norrby-Teglund A. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin Infect Dis. 2010; 51 (1): 58-65.

  21. Johansson L, Linner A, Sunden-Cullberg J, Haggar A, Herwald H, Loré K et al. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. J Immunol. 2009; 183 (6): 4047-4054.

  22. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014; 370 (10): 1412-1421.

  23. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998; 64 (5): 397-400.

  24. Vieillard-Baron A. Septic cardiomyopathy. Ann Intensive Care. 2011; 1 (1): 6.

  25. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007; 38 Suppl. 5: S19-26.

  26. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology and determinants of mortality. J Bone Joint Surg Am. 2003; 85-A (8): 1454-1460.

  27. Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014; 59 (3): 358-365.

  28. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59 (2): e10-52.

  29. Berlot G, Rossini P, Turchet F. Biology of immunoglobulin’s. Transl Med UniSa. 2014; 11: 24-27.

  30. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999; 28 (4): 800-807.

  31. Linner A, Darenberg J, Sjolin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome a comparative observational study. Clin Infect Dis. 2014; 59 (6): 851-857.




2020     |     www.medigraphic.com